Positive Data, Financial Strategies, Marketing Authorizations, and Collaborations Promote Growth in Biotech Companies - Research

      Positive Data, Financial Strategies, Marketing Authorizations, and
Collaborations Promote Growth in Biotech Companies - Research Report on Biogen
            Idec, MannKind, Aegerion, Ariad, and Seattle Genetics

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, July 10, 2013

NEW YORK, July 10, 2013 /PRNewswire/ --

Today, Wall Street Reports announced new research reports highlighting Biogen
Idec Inc. (NASDAQ: BIIB), MannKind Corp. (NASDAQ: MNKD), Aegerion
Pharmaceuticals, Inc. (NASDAQ: AEGR), Ariad Pharmaceuticals Inc. (NYSE: ARIA),
and Seattle Genetics Inc. (NASDAQ: SGEN). Today's readers may access these
reports free of charge - including full price targets, industry analysis and
analyst ratings - via the links below.

Biogen Idec Inc. Research Report

On July 4, 2013, Biogen Idec Inc. (Biogen Idec) and Swedish Orphan Biovitrum
AB (publ) (Sobi) released new data supporting the clinical and safety profile
of ELOCTATE, a long-lasting recombinant factor VIII candidate for hemophilia
A. Glenn Pierce, M.D., Ph.D., Senior Vice President of Global Medical Affairs
and Chief Medical Officer of Biogen Idec's Hemophilia Therapeutic Area, said,
"We are excited to share these new data, which include patients' and
physicians' assessment of ELOCTATE's efficacy in treating bleeding episodes
and in controlling bleeding during surgery." Pierce continued, "The A-LONG
data presented at ISTH support the potential of ELOCTATE to enable longer
intervals between prophylactic (preventative) injections compared to the
current standard of care." The Full Research Report on Biogen Idec Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.WSReports.com/r/full_research_report/b35f_BIIB]

--

MannKind Corp. Research Report

On July 1, 2013, MannKind Corp. (MannKind) announced that it has entered into
a secured financing with affiliates of Deerfield Management Company L.P.
(Deerfield). MannKind reported that Deerfield has committed to purchase up to
$160 million of its senior secured notes under the financing agreement. Alfred
E. Mann, CEO of MannKind, commented, "We worked with Deerfield to structure a
facility that aligns with our near- and long-term strategy to achieve
important development, commercial and strategic milestones while minimizing
near term dilution." Mann added, "We are encouraged by Deerfield's confidence
in the potential of AFREZZA." The Full Research Report on MannKind Corp. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.WSReports.com/r/full_research_report/0b44_MNKD]

--

Aegerion Pharmaceuticals, Inc. Research Report

On July 5, 2013, Aegerion Pharmaceuticals, Inc. (Aegerion) announced that on
July 1, 2013, it granted stock options to purchase an aggregate of 19,700
shares of common stock to five new employees under the inducement stock option
program. The Company also reported that the Compensation Committee of the
Company's Board of Directors approved the reservation of 1 million shares of
common stock to be used exclusively for the grant of non-qualified stock
options to individuals who were not previously an employee or non-employee
director of Aegerion (or following a bona fide period of non-employment), as
an inducement new hire stock option award material to an individual's entry
into employment within the meaning of Rule 5635(c)(4) of the NASDAQ Listing
Rules (Inducement Stock Options). The Full Research Report on Aegerion
Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:
[http://www.WSReports.com/r/full_research_report/a1f4_AEGR]

--

Ariad Pharmaceuticals Inc. Research Report

On July 2, 2013, Ariad Pharmaceuticals Inc. (Ariad) announced that Iclusig
(ponatinib) has been granted marketing authorization by the European
Commission (EC) as an orphan medicinal product for two indications: for the
treatment of adult patients with chronic phase, accelerated phase or blast
phase chronic myeloid leukemia (CML) who are resistant to dasatinib or
nilotinib; who are intolerant to dasatinib or nilotinib and for whom
subsequent treatment with imatinib is not clinically appropriate; or who have
the T315I mutation, and secondly. for the treatment of adult patients with
Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL) who
are resistant to dasatinib; who are intolerant to dasatinib and for whom
subsequent treatment with imatinib is not clinically appropriate; or who have
the T315I mutation. Harvey J. Berger, M.D., Chairman and CEO of Ariad,
commented, "We are delighted by the rapid approval of Iclusig in Europe and
will now work closely with the national health authorities to make Iclusig
available to Philadelphia-positive leukemia patients as quickly as possible."

The Full Research Report on Ariad Pharmaceuticals Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.WSReports.com/r/full_research_report/1015_ARIA]

--

Seattle Genetics Inc. Research Report

On June 27, 2013, Seattle Genetics Inc. (Seattle Genetics) and Agensys, Inc.,
announced that Seattle Genetics has exercised an option to co-develop an
additional antibody-drug conjugate (ADC) under the companies' existing ADC
collaboration agreement. Eric L. Dobmeier, Chief Operating Officer of Seattle
Genetics, stated, "Through our collaboration and co-development agreements
with companies like Agensys/Astellas, Seattle Genetics continues to enhance
its ability to innovate by combining our industry-leading ADC technology with
proprietary cancer targets and antibodies to develop potential new treatments
for patients with cancer." Dobmeier added, "ADCs represent a novel therapeutic
approach, and through our pipeline and collaborations more than half of the
ADC candidates in clinical development utilize our technology. We look forward
to working with Agensys/Astellas to advance ASG-15ME." The Full Research
Report on Seattle Genetics Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:
[http://www.WSReports.com/r/full_research_report/f796_SGEN]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by a CFA. However, we are only human and are prone to
    make mistakes. If you notice any errors or omissions, please notify us
    below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through Chartered Financial
Analysts, only reviewed the information provided by Equity News Network in
this article or report according to the Procedures outlined by Equity News
Network. Equity News Network is not entitled to veto or interfere in the
application of such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

SOURCE Wall Street Reports

Contact: WSReports.com Phone #: +1-310-496-8071 (North America)
 
Press spacebar to pause and continue. Press esc to stop.